Absence of cardiac toxicity of zidovudine in infants

Steven E Lipshultz, Kirk A. Easley, E. John Orav, Samuel Kaplan, Thomas J. Starc, J. Timothy Bricker, Wyman W. Lai, Douglas S. Moodie, George Sopko, Kenneth McIntosh, Steven D. Colan

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Background: Some evidence suggests that perinatal exposure to zidovudine may cause cardiac abnormalities in infants. We prospectively studied left ventricular structure and function in infants born to mothers infected with the human immunodeficiency virus (HIV) in order to determine whether there was evidence of zidovudine cardiac toxicity after perinatal exposure. Methods: We followed a group of infants born to HIV-infected women from birth to five years of age with echocardiographic studies every four to six months. Serial echocardiograms were obtained for 382 infants without HIV infection (36 with zidovudine exposure) and 58 HIV-infected infants (12 with zidovudine exposure). Repeated-measures analysis was used to examine four measures of left ventricular structure and function during the first 14 months of life in relation to zidovudine exposure. Results: Zidovudine exposure was not associated with significant abnormalities in mean left ventricular fractional shortening, end-diastolic dimension, contractility, or mass in either non-HIV-infected or HIV-infected infants. Among infants without HIV infection, the mean fractional shortening at 10 to 14 months was 38.1 percent for those never exposed to zidovudine and 39.0 percent for those exposed to zidovudine (mean difference, -0.9 percentage point; 95 percent confidence interval, -3.1 to 1.3 percentage points; P = 0.43). Among HIV-infected infants, the mean fractional shortening at 10 to 14 months was similar in those never exposed to zidovudine (35.4 percent) and those exposed to the drug (35.3 percent) (mean difference, 0.1 percentage point; 95 percent confidence interval, -3.7 to 3.9 percentage points; P = 0.95). Zidovudine exposure was not significantly related to depressed fractional shortening (shortening of 25 percent or less) during the first 14 months of life. No child over the age of 10 months had depressed fractional shortening. Conclusions: Zidovudine was not associated with acute or chronic abnormalities in left ventricular structure or function in infants exposed to the drug in the perinatal period. (C) 2000, Massachusetts Medical Society.

Original languageEnglish
Pages (from-to)759-766
Number of pages8
JournalNew England Journal of Medicine
Volume343
Issue number11
DOIs
StatePublished - Sep 14 2000
Externally publishedYes

Fingerprint

Zidovudine
HIV
Virus Diseases
Left Ventricular Function
Cardiotoxicity
Confidence Intervals
Medical Societies
Pharmaceutical Preparations
Mothers
Parturition
Viruses

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lipshultz, S. E., Easley, K. A., Orav, E. J., Kaplan, S., Starc, T. J., Bricker, J. T., ... Colan, S. D. (2000). Absence of cardiac toxicity of zidovudine in infants. New England Journal of Medicine, 343(11), 759-766. https://doi.org/10.1056/NEJM200009143431102

Absence of cardiac toxicity of zidovudine in infants. / Lipshultz, Steven E; Easley, Kirk A.; Orav, E. John; Kaplan, Samuel; Starc, Thomas J.; Bricker, J. Timothy; Lai, Wyman W.; Moodie, Douglas S.; Sopko, George; McIntosh, Kenneth; Colan, Steven D.

In: New England Journal of Medicine, Vol. 343, No. 11, 14.09.2000, p. 759-766.

Research output: Contribution to journalArticle

Lipshultz, SE, Easley, KA, Orav, EJ, Kaplan, S, Starc, TJ, Bricker, JT, Lai, WW, Moodie, DS, Sopko, G, McIntosh, K & Colan, SD 2000, 'Absence of cardiac toxicity of zidovudine in infants', New England Journal of Medicine, vol. 343, no. 11, pp. 759-766. https://doi.org/10.1056/NEJM200009143431102
Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT et al. Absence of cardiac toxicity of zidovudine in infants. New England Journal of Medicine. 2000 Sep 14;343(11):759-766. https://doi.org/10.1056/NEJM200009143431102
Lipshultz, Steven E ; Easley, Kirk A. ; Orav, E. John ; Kaplan, Samuel ; Starc, Thomas J. ; Bricker, J. Timothy ; Lai, Wyman W. ; Moodie, Douglas S. ; Sopko, George ; McIntosh, Kenneth ; Colan, Steven D. / Absence of cardiac toxicity of zidovudine in infants. In: New England Journal of Medicine. 2000 ; Vol. 343, No. 11. pp. 759-766.
@article{23c97226234b4dc6b7e71dfb257ab404,
title = "Absence of cardiac toxicity of zidovudine in infants",
abstract = "Background: Some evidence suggests that perinatal exposure to zidovudine may cause cardiac abnormalities in infants. We prospectively studied left ventricular structure and function in infants born to mothers infected with the human immunodeficiency virus (HIV) in order to determine whether there was evidence of zidovudine cardiac toxicity after perinatal exposure. Methods: We followed a group of infants born to HIV-infected women from birth to five years of age with echocardiographic studies every four to six months. Serial echocardiograms were obtained for 382 infants without HIV infection (36 with zidovudine exposure) and 58 HIV-infected infants (12 with zidovudine exposure). Repeated-measures analysis was used to examine four measures of left ventricular structure and function during the first 14 months of life in relation to zidovudine exposure. Results: Zidovudine exposure was not associated with significant abnormalities in mean left ventricular fractional shortening, end-diastolic dimension, contractility, or mass in either non-HIV-infected or HIV-infected infants. Among infants without HIV infection, the mean fractional shortening at 10 to 14 months was 38.1 percent for those never exposed to zidovudine and 39.0 percent for those exposed to zidovudine (mean difference, -0.9 percentage point; 95 percent confidence interval, -3.1 to 1.3 percentage points; P = 0.43). Among HIV-infected infants, the mean fractional shortening at 10 to 14 months was similar in those never exposed to zidovudine (35.4 percent) and those exposed to the drug (35.3 percent) (mean difference, 0.1 percentage point; 95 percent confidence interval, -3.7 to 3.9 percentage points; P = 0.95). Zidovudine exposure was not significantly related to depressed fractional shortening (shortening of 25 percent or less) during the first 14 months of life. No child over the age of 10 months had depressed fractional shortening. Conclusions: Zidovudine was not associated with acute or chronic abnormalities in left ventricular structure or function in infants exposed to the drug in the perinatal period. (C) 2000, Massachusetts Medical Society.",
author = "Lipshultz, {Steven E} and Easley, {Kirk A.} and Orav, {E. John} and Samuel Kaplan and Starc, {Thomas J.} and Bricker, {J. Timothy} and Lai, {Wyman W.} and Moodie, {Douglas S.} and George Sopko and Kenneth McIntosh and Colan, {Steven D.}",
year = "2000",
month = "9",
day = "14",
doi = "10.1056/NEJM200009143431102",
language = "English",
volume = "343",
pages = "759--766",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "11",

}

TY - JOUR

T1 - Absence of cardiac toxicity of zidovudine in infants

AU - Lipshultz, Steven E

AU - Easley, Kirk A.

AU - Orav, E. John

AU - Kaplan, Samuel

AU - Starc, Thomas J.

AU - Bricker, J. Timothy

AU - Lai, Wyman W.

AU - Moodie, Douglas S.

AU - Sopko, George

AU - McIntosh, Kenneth

AU - Colan, Steven D.

PY - 2000/9/14

Y1 - 2000/9/14

N2 - Background: Some evidence suggests that perinatal exposure to zidovudine may cause cardiac abnormalities in infants. We prospectively studied left ventricular structure and function in infants born to mothers infected with the human immunodeficiency virus (HIV) in order to determine whether there was evidence of zidovudine cardiac toxicity after perinatal exposure. Methods: We followed a group of infants born to HIV-infected women from birth to five years of age with echocardiographic studies every four to six months. Serial echocardiograms were obtained for 382 infants without HIV infection (36 with zidovudine exposure) and 58 HIV-infected infants (12 with zidovudine exposure). Repeated-measures analysis was used to examine four measures of left ventricular structure and function during the first 14 months of life in relation to zidovudine exposure. Results: Zidovudine exposure was not associated with significant abnormalities in mean left ventricular fractional shortening, end-diastolic dimension, contractility, or mass in either non-HIV-infected or HIV-infected infants. Among infants without HIV infection, the mean fractional shortening at 10 to 14 months was 38.1 percent for those never exposed to zidovudine and 39.0 percent for those exposed to zidovudine (mean difference, -0.9 percentage point; 95 percent confidence interval, -3.1 to 1.3 percentage points; P = 0.43). Among HIV-infected infants, the mean fractional shortening at 10 to 14 months was similar in those never exposed to zidovudine (35.4 percent) and those exposed to the drug (35.3 percent) (mean difference, 0.1 percentage point; 95 percent confidence interval, -3.7 to 3.9 percentage points; P = 0.95). Zidovudine exposure was not significantly related to depressed fractional shortening (shortening of 25 percent or less) during the first 14 months of life. No child over the age of 10 months had depressed fractional shortening. Conclusions: Zidovudine was not associated with acute or chronic abnormalities in left ventricular structure or function in infants exposed to the drug in the perinatal period. (C) 2000, Massachusetts Medical Society.

AB - Background: Some evidence suggests that perinatal exposure to zidovudine may cause cardiac abnormalities in infants. We prospectively studied left ventricular structure and function in infants born to mothers infected with the human immunodeficiency virus (HIV) in order to determine whether there was evidence of zidovudine cardiac toxicity after perinatal exposure. Methods: We followed a group of infants born to HIV-infected women from birth to five years of age with echocardiographic studies every four to six months. Serial echocardiograms were obtained for 382 infants without HIV infection (36 with zidovudine exposure) and 58 HIV-infected infants (12 with zidovudine exposure). Repeated-measures analysis was used to examine four measures of left ventricular structure and function during the first 14 months of life in relation to zidovudine exposure. Results: Zidovudine exposure was not associated with significant abnormalities in mean left ventricular fractional shortening, end-diastolic dimension, contractility, or mass in either non-HIV-infected or HIV-infected infants. Among infants without HIV infection, the mean fractional shortening at 10 to 14 months was 38.1 percent for those never exposed to zidovudine and 39.0 percent for those exposed to zidovudine (mean difference, -0.9 percentage point; 95 percent confidence interval, -3.1 to 1.3 percentage points; P = 0.43). Among HIV-infected infants, the mean fractional shortening at 10 to 14 months was similar in those never exposed to zidovudine (35.4 percent) and those exposed to the drug (35.3 percent) (mean difference, 0.1 percentage point; 95 percent confidence interval, -3.7 to 3.9 percentage points; P = 0.95). Zidovudine exposure was not significantly related to depressed fractional shortening (shortening of 25 percent or less) during the first 14 months of life. No child over the age of 10 months had depressed fractional shortening. Conclusions: Zidovudine was not associated with acute or chronic abnormalities in left ventricular structure or function in infants exposed to the drug in the perinatal period. (C) 2000, Massachusetts Medical Society.

UR - http://www.scopus.com/inward/record.url?scp=0034648743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034648743&partnerID=8YFLogxK

U2 - 10.1056/NEJM200009143431102

DO - 10.1056/NEJM200009143431102

M3 - Article

C2 - 10984563

AN - SCOPUS:0034648743

VL - 343

SP - 759

EP - 766

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 11

ER -